/
/
Clinical Trial: Nivolumab, Lenalidomide, and Dexamethasone In High-Risk Smoldering Multiple Myeloma
Clinical Trial: Nivolumab, Lenalidomide, and Dexamethasone In High-Risk Smoldering Multiple Myeloma image
Clinical Trial: Nivolumab, Lenalidomide, and Dexamethasone In High-Risk Smoldering Multiple Myeloma
Posted Sep 01, 2017

This research study is evaluating a new immunotherapy drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. - Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.

What treatments are used in this trial?
- Dexamethasone ( Steroid ) 
- Lenalidomide ( Immunomodulatory Drugs (IMID) ) 
- Nivolumab ( Checkpoint Inhibitor ,  Immunotherapy ,  Monoclonal Antibody )

There are 9 active sites including: City of Hope (southern CA), Pacific Cancer Care (northern CA), Colorado Blood Cancer Institute, Winship Cancer Institute (Georgia), Dana Farber Cancer Institute (MA), Beth Israel Deaconess Medical Center (MA), University of Michigan (MI), Barbara Ann Karmanos Cancer Institute (MI), Sarah Cannon (TN).

To learn more about this trial and sign up to receive notifications, click here:

Study of the CD38 Antibody Daratumumab Clinical Trial To find all eligible clinical trials, click here: Study of the CD38 Antibody Daratumumab Clinical Trial
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811